Winterlight Labs Competitors

The University of Southern California is a leading private research university located in Los Angeles, the capital of the Pacific Rim. This is the official LinkedIn presence for the University of Southern California. This account is managed and mediated by the staff of USC University Communications. Content (including posts from 3rd parties) that include videos, photographs, opinions and links to content outside of this channel do not necessarily represent the University of Southern California’s academic goals or opinions. Community guidelines: Alumni and students are welcome to post professional updates and news. Posts containing solicitations, product placements, derogatory or inflammatory comments are prohibited and will be removed. Off-topic comments will also be removed. Posts are not regularly monitored. Please note: for questions regarding degrees offered and admissions policies please call (213) 740-2311.

Oura is an award-winning, fast-growing startup that helps people get up close and personal with their health. The Oura Ring and Oura App provide daily insights into sleep, activity, stress, recovery and much more. By providing daily feedback and practical steps to inspire healthy lifestyles, we've helped millions of people improve their sleep, understand their bodies, and transform their health. We’re on a mission to empower every person to own their inner potential, and we’re seeking talented individuals to join us on our journey. JOIN THE OURA TEAM We are a multi-disciplinary team of over 100 experts in hardware engineering, software development, machine learning, bioscience, sleep, industrial and UX design, production, marketing and customer experience. We always strive to learn more and dig deeper into our research and analytics, to stay engaged and creative in everything we do. We are uncompromising in delivering value to our members and our partners across the globe.. Ouraring Inc. is headquartered in San Francisco, CA

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and efficacy profile of its active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com